Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > FGF R2 (IIIb)


Brief Information

Name:Fibroblast growth factor receptor 2
Target Synonym:EC:,EC 2.7.10,BEK,K-sam,KGFR,FGFR2,Fibroblast Growth Factor Receptor 2,Keratinocyte Growth Factor Receptor,Bacteria-Expressed Kinase,Protein Tyrosine Kinase, Receptor Like 14,BEK Fibroblast Growth Factor Receptor,Craniofacial Dysostosis 1,Jackson-Weiss Syndrome,Pfeiffer Syndrome,Crouzon Syndrome,CD332 Antigen,EC,FGFR-2,BFR-1,CD332,BBDS,CEK3,ECT1,TK14,TK25,CFD1,KSAM,JWS,Receptor, Fibroblast Growth Factor, Type 2
Number of Launched Drugs:7
Number of Drugs in Clinical Trials:28
Lastest Research Phase:Approved

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data


Biotinylated Human FGF-10, His,Avitag (Cat. No. FG0-H81Q7) immobilized on SA Chip can bind Human FGFR2 (IIIb), His Tag (Cat. No. FGB-H5223) with an affinity constant of 5.02 μM as determined in a SPR assay (Biacore 8K) (Routinely tested).


Immobilized Mouse FGFR2 (IIIb), His Tag (Cat. No. FGB-M52H5) at 5 μg/mL (100 μL/well) can bind Biotinylated Human FGF basic, Avitag,His Tag (Cat. No. FGC-H81E3) with a linear range of 0.039-1.25 μg/mL (QC tested).

Synonym Name



Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation, migration and apoptosis, and in the regulation of embryonic development. Required for normal embryonic patterning, trophoblast function, limb bud development, lung morphogenesis, osteogenesis and skin development. Plays an essential role in the regulation of osteoblast differentiation, proliferation and apoptosis, and is required for normal skeleton development. Promotes cell proliferation in keratinocytes and immature osteoblasts, but promotes apoptosis in differentiated osteoblasts. Phosphorylates PLCG1, FRS2 and PAK4. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. FGFR2 signaling is down-regulated by ubiquitination, internalization and degradation. Mutations that lead to constitutive kinase activation or impair normal FGFR2 maturation, internalization and degradation lead to aberrant signaling. Over-expressed FGFR2 promotes activation of STAT1.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Infigratinib BGJ-398; NVP-BGJ398 Approved Novartis Pharma Ag TRUSELTIQ United States Cholangiocarcinoma Helsinn Healthcare Sa 2021-05-28 Nasopharyngeal Neoplasms; Uterine Cervical Neoplasms; Adenocarcinoma; Glioma; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Gastrointestinal Stromal Tumors; Oropharyngeal Neoplasms; Cholangiocarcinoma; Central Nervous System Neoplasms; Urinary Bladder Neoplasms; Colonic Neoplasms; Biliary Tract Neoplasms; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Achondroplasia; Papillomavirus Infections; Neoplasms; Squamous Cell Carcinoma of Head and Neck; Rectal Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Hematologic Neoplasms; Solid tumours Details
Futibatinib TAS-120 Approved Taiho Pharmaceutical Co Ltd, Otsuka Pharmaceutical Co Ltd LYTGOBI United States Cholangiocarcinoma Taiho Oncology Inc 2022-09-30 Solid tumours; Bone Marrow Neoplasms; Stomach Neoplasms; Carcinoma; Esophageal Neoplasms; Neoplasms; Carcinoma, Transitional Cell; Central Nervous System Neoplasms; Breast Neoplasms; Cholangiocarcinoma; Sarcoma; Lymphoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung Details
Nintedanib Esylate BIBF-1120 Approved C.H. Boehringer Sohn Ag & Co. Kg Ofev, Vargatef EU systemic sclerosis-associated interstitial lung disease Boehringer Ingelheim International Gmbh 2014-10-15 Gliosarcoma; Breast Neoplasms; Sarcoma; systemic sclerosis-associated interstitial lung disease; Adenocarcinoma, Clear Cell; Peritoneal Neoplasms; Colorectal Neoplasms; Astrocytoma; Hepatic Insufficiency; Genital Neoplasms, Female; Silicosis; Prostatic Neoplasms; Carcinoma, Squamous Cell; Appendiceal Neoplasms; Fallopian Tube Neoplasms; Leukemia, Myeloid, Acute; Uterine Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Colonic Neoplasms; Ovarian Neoplasms; Telangiectasia, Hereditary Hemorrhagic; Esophageal Neoplasms; Rejection of lung transplantation; Carcinoid Tumor; Endometrial Stromal Tumors; Carcinoma, Renal Cell; Radiation Pneumonitis; Neoplasms; Idiopathic Pulmonary Fibrosis; Solid tumours; Scleroderma, Systemic; Glioblastoma; Small Cell Lung Carcinoma; Mesothelioma; Neuroendocrine Tumors; Pulmonary Fibrosis; Lung Diseases, Interstitial; Multiple Myeloma; Asbestosis; Oligodendroglioma Details
Lenvatinib Mesylate ER-203492-00; E-7080; MK-7902 Approved Eisai Co Ltd Kisplyx, Lenvima, Lenvima/Kisplyx, 乐卫玛 Japan Carcinoma, Renal Cell Merck Sharp & Dohme Corp 2015-02-13 Liver Diseases; Paraganglioma; Neoplasm Metastasis; Thyroid Cancer, Papillary; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Glioma; Lymphoma; Endometrial Neoplasms; Thyroid Neoplasms; Hepatic Insufficiency; Osteosarcoma; Cholangiocarcinoma; Breast Neoplasms; Solid tumours; Neuroendocrine Tumors; Carcinoma, Adenoid Cystic; Adenocarcinoma, Follicular; Kidney Diseases; Neoplasms; Adenocarcinoma of Lung; Thyroid Carcinoma, Anaplastic; Pheochromocytoma; Renal Insufficiency; Esophageal Neoplasms; Carcinoma, Renal Cell; Ovarian Neoplasms; Liver Neoplasms; Biliary Tract Neoplasms Details
Regorafenib DAST; BAY-73-4506 Approved Bayer AG Stivarga, Resihance Mainland China Gastrointestinal Stromal Tumors Bayer Pharma Ag 2012-09-27 Leukemia, Myeloid, Acute; Sarcoma; Gastrinoma; Osteosarcoma; Sarcoma, Ewing; Colorectal Neoplasms; Peritoneal Neoplasms; Gastrointestinal Stromal Tumors; Bile Duct Neoplasms; Fallopian Tube Neoplasms; Esophageal adenocarcinoma; Adenoma; Thyroid Neoplasms; Lung Neoplasms; Thymoma; Carcinoma, Hepatocellular; Adenocarcinoma; Melanoma; Neoplasm Metastasis; Gastrointestinal Neoplasms; Somatostatinoma; Carcinoma, Islet Cell; Ovarian Neoplasms; Liver Neoplasms; Hemangiosarcoma; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Rectal Neoplasms; Carcinoid Tumor; Insulinoma; Solid tumours; Colonic Neoplasms; Neoplasms; Carcinoma, Ovarian Epithelial; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Glioblastoma; Carcinoma, Transitional Cell; Carcinoma, Adenoid Cystic; Glucagonoma Details
Anlotinib Dihydrochloride AL-3818 Approved Advenchen Laboratories Llc, Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd 福可维 Mainland China Thyroid Neoplasms Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd 2018-05-08 Esophageal Squamous Cell Carcinoma; Bone Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Hepatic Insufficiency; Gastrointestinal Stromal Tumors; Urologic Neoplasms; Sarcoma, Alveolar Soft Part; Endometrial Neoplasms; Gallbladder Neoplasms; Bile Duct Diseases; Thyroid Neoplasms; Fallopian Tube Neoplasms; Lung Neoplasms; Glioma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma; Carcinoma, Hepatocellular; Osteoma; Small Cell Lung Carcinoma; Head and Neck Neoplasms; Solid tumours; Biliary Tract Neoplasms; Drug-Related Side Effects and Adverse Reactions; Ovarian Neoplasms; Esophageal Neoplasms; Thoracic Neoplasms; Carcinoma, Renal Cell; Stomach Neoplasms; Leiomyosarcoma; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Carcinoma, Ovarian Epithelial; Sarcoma, Synovial; Neuroendocrine Tumors; Liver Diseases; Sarcoma; Medullary thyroid cancer (MTC); Nasopharyngeal Carcinoma Details
Erdafitinib 890E37NHMV; JNJ-42756493; G-024; JNJ-493 Approved Astex Pharmaceuticals Inc Balversa South Korea Carcinoma, Transitional Cell Janssen Biotech Inc 2019-04-12 Neoplasms, Neuroepithelial; Osteosarcoma; Neuroblastoma; Breast Neoplasms; Urologic Neoplasms; Hepatic Insufficiency; Histiocytic Sarcoma; Bile Duct Neoplasms; Lymphoma; Lymphoma, Non-Hodgkin; Sarcoma; Glioma; Carcinoma, Squamous Cell; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Xanthogranuloma, Juvenile; Neoplasms, Germ Cell and Embryonal; Neuroectodermal Tumors, Primitive, Peripheral; Rhabdoid Tumor; Hematologic Neoplasms; Rhabdomyosarcoma; Ependymoma; Medulloblastoma; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma; Hepatoblastoma; Solid tumours; Neoplasms; Carcinoma, Transitional Cell; Wilms Tumor; Multiple Myeloma; Urinary Bladder Neoplasms; Central Nervous System Neoplasms; Histiocytosis, Langerhans-Cell; Sarcoma, Ewing Details
Pemigatinib INCB-054828; INCB-54828; IBI-375 Approved Incyte Corp Pemazyre, 伯坦, 达伯坦 Mainland China Biliary Tract Neoplasms Innovent Biologics(Suzhou) Co Ltd 2020-04-17 Translocation, Genetic; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Glioma; Lung Neoplasms; Endometrial Neoplasms; Bile Duct Neoplasms; Colitis, Ulcerative; Urologic Neoplasms; Colorectal Neoplasms; Breast Neoplasms; Cholangiocarcinoma; Solid tumours; Multiple Myeloma; Urinary Bladder Neoplasms; Glioblastoma; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Myeloproliferative Disorders; Neoplasms; Carcinoma, Renal Cell; Stomach Neoplasms; Carcinoma; Biliary Tract Neoplasms Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
BPI-17509 BPI-17509 Phase 1 Clinical Betta Pharmaceuticals Co Ltd Solid tumours Details
CPL-304110 CPL-304110; CPL-304-110 Celon Pharma Sa Details
R-1530 RG1530; R-1530; RG-1530 F. Hoffmann-La Roche Ltd Details
LY-2874455 LY-2874455 Eli Lilly And Company Details
TT-00434 TT-00434 Phase 1 Clinical TransThera Sciences (Nanjing) Inc Solid tumours; Urinary Bladder Neoplasms Details
Aprutumab ixadotin BAY-1187982 Bayer AG Details
DS-1123 DS-1123; DS-1123a Daiichi Sankyo Co Ltd Details
ODM-203 ODM-203 Orion Corp Details
Aprutumab FGFR-moAb; FGFR2-TTC; BAY-1179470 Bayer AG Details
SC-0011 SC-0011 Phase 1 Clinical Shijiazhuang Zhikang Hongren New Drug Development Co Ltd Solid tumours Details
Efruxifermin AKR-001; AMG-876; EFX Phase 2 Clinical Amgen Inc Non-alcoholic Fatty Liver Disease; Diabetes Mellitus Details
Derazantinib ARQ-087.2HCl; AQ-14741087; ARQ-087; BAL-087 Phase 2 Clinical Arqule Inc Solid tumours; Biliary Tract Neoplasms; Stomach Neoplasms; Carcinoma, Transitional Cell; Cholangiocarcinoma; Urogenital Neoplasms; Carcinoma, Hepatocellular Details
Lucitanib AL-3810; CO-3810; S-80881 Phase 3 Clinical Advenchen Laboratories Nanjing Ltd Solid tumours; Stomach Neoplasms; Small Cell Lung Carcinoma; Breast Neoplasms; Nasopharyngeal Carcinoma; Colorectal Neoplasms; Genital Neoplasms, Female; Thymus Neoplasms; Carcinoma, Small Cell; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular Details
Zoligratinib CH-5183284; FF-284; Debio-1347 Phase 2 Clinical Chugai Pharmaceutical Co Ltd Solid tumours; Breast Neoplasms Details
KIN-3248 KIN-3248; KIN-003 Phase 1 Clinical Kinnate Biopharma Inc Solid tumours; Carcinoma, Transitional Cell; Cholangiocarcinoma Details
HH185 3-D185; HH-185; 3D185; 3D-185 Phase 2 Clinical Shanghai Medicilon Inc, ShangHai HaiHe Biopharma Co Ltd, Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Solid tumours; Cholangiocarcinoma Details
Gunagratinib ICP-192 Phase 2 Clinical Beijing Tiancheng Pharmaceutical Technology Co Ltd Solid tumours; Head and Neck Neoplasms; Biliary Tract Neoplasms; Stomach Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Urinary Bladder Neoplasms; Cholangiocarcinoma; Lung Neoplasms Details
Rogaratinib BAY-1163877 Phase 2 Clinical Bayer AG Solid tumours; Carcinoma, Transitional Cell; Neoplasms; Urinary Bladder Neoplasms; Sarcoma; Breast Neoplasms; Gastrointestinal Stromal Tumors; Carcinoma, Non-Small-Cell Lung Details
RLY-4008 RLY-4008 Phase 2 Clinical Relay Therapeutics Inc Cholangiocarcinoma; Translocation, Genetic Details
Tasurgratinib E-7090 Phase 2 Clinical Eisai Co Ltd Biliary Tract Neoplasms; Solid tumours; Neoplasms; Cholangiocarcinoma; Breast Neoplasms; Hepatic Insufficiency Details
ABSK-061 ABSK061 Phase 1 Clinical ABbisko Therapeutics Co Ltd Solid tumours Details
Bemarituzumab FPA-144 Phase 3 Clinical Five Prime Therapeutics Inc Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Neoplasms; Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Carcinoma, Squamous Cell; Adenocarcinoma; Gastrointestinal Neoplasms Details
Alofanib RPT-835 Phase 1 Clinical Russian Pharmaceutical Technologies Llc Stomach Neoplasms Details
HMPL-453 HMPL-453 Phase 2 Clinical Solid tumours; Biliary Tract Neoplasms; Neoplasms, Mesothelial; Mesothelioma; Cholangiocarcinoma; Bile Duct Neoplasms Details
ABSK-121 ABSK121; ABSK121-NX Phase 1 Clinical ABbisko Therapeutics Co Ltd Solid tumours Details
AZD-4547 AZD-4547; ABSK-091; AZD4547; ABSK091 Phase 2 Clinical Astrazeneca Plc Uterine Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Carcinoma, Squamous Cell; Esophageal adenocarcinoma; Endometrial Neoplasms; Lung Neoplasms; Multiple Myeloma; Thyroid Neoplasms; Lymphoma; Glioma; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Uterine Cervical Neoplasms; Melanoma; Foodborne Diseases; Squamous Cell Carcinoma of Head and Neck; Hematologic Neoplasms; Ovarian Neoplasms; Liver Neoplasms; Stomach Neoplasms; Gastrointestinal Diseases; Esophageal Neoplasms; Rectal Neoplasms; Carcinoma, Renal Cell; Solid tumours; Carcinoma, Transitional Cell; Neoplasms; Skin Neoplasms; Pancreatic Neoplasms; Carcinoma, Ovarian Epithelial; Colonic Neoplasms; Urinary Bladder Neoplasms Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message